Clint Witchalls's profile photo

Clint Witchalls

Brixton, London

Senior Health Editor at The Conversation

Senior health editor @ConversationUK Views are my own.

Articles

  • Sep 6, 2023 | tolerance.ca | Clint Witchalls

    © 2023 Tolerance.ca® Inc. All reproduction rights reserved. All information reproduced on the Web pages of www.tolerance.ca (including articles, images, photographs, and logos) is protected by intellectual property rights owned by Tolerance.ca® Inc. or, in certain cases, by its author. Any reproduction of the information for use other than personal use is prohibited.

  • Sep 6, 2023 | theconversation.com | Clint Witchalls

    In February 2021, The Conversation reported on a trial for a new weight-loss drug, called semaglutide, that was being hailed in the media as a “gamechanger”. Gamechanger is a word used far too often by journalists to describe things that are, frankly, mundane. This time, though, the word seems apt. In the past two and a half years, a lot of ink has been spilt discussing the merits and demerits of this drug – better known by its brand names Ozempic and Wegovy – including in The Conversation.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
1K
Tweets
1K
DMs Open
No
No Tweets found.